Lobeglitazone and pioglitazone as add-ons to metformin for patients with type 2 diabetes: A 24-week, multicentre, randomized, double-blind, parallel-group, active-controlled, phase III clinical trial with a 28-week extension

S. M. Jin, C. Y. Park, Y. M. Cho, B. J. Ku, C. W. Ahn, B. S. Cha, K. W. Min, Y. A. Sung, S. H. Baik, K. W. Lee, K. H. Yoon, M. K. Lee, S. W. Park

Research output: Contribution to journalArticlepeer-review

40 Scopus citations

Fingerprint

Dive into the research topics of 'Lobeglitazone and pioglitazone as add-ons to metformin for patients with type 2 diabetes: A 24-week, multicentre, randomized, double-blind, parallel-group, active-controlled, phase III clinical trial with a 28-week extension'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science